Increased airway hyperresponsiveness to adenosine in patients with aspirin intolerant asthma Dear Editor, Airway hyperresponsiveness in bronchial asthma is commonly evaluated by inhalation of methacholine (Mch) or histamine. Asthma patients also show bronchoconstriction upon adenosine inhalation.
patients. 6 Based on these findings, we hypothesized that MCs would show greater activation in AIA than in non-AIA, and that AIA patients would be more hypersensitive to AMP compared with non-AIA patients. To test these hypotheses, we compared the results of inhalation challenge tests using AMP and Mch conducted in patients with bronchial asthma diagnosed with AIA or non-AIA. The Ethics Committee of Fujita Health University (Toyoake, Aichi, Japan) approved our study protocol. Study participants were 30 patients treated for bronchial asthma at an outpatient clinic in our hospital. Patients who reported an infection of the upper respiratory tract or attack of bronchial asthma within 4 weeks before the examination were excluded from the study. Among these 30 patients, 12 were diagnosed with AIA (4 males and 8 females; mean age, 42.6 years) and 18 with non-AIA (5; 13; 42.1 years). Characteristics, laboratory findings, and therapy of studied patients are shown in Table 1 .
The diagnosis of AIA was confirmed by: inhalation provocation tests using tolmetin or sulpyrine; oral aspirin provocation test with a history of asthma attacks induced by nonsteroidal antiinflammatory drugs (NSAIDs). 7 Patients with a negative result of the inhalation challenge test using sulpyrine/tolmetin, or oral aspirin provocation test with no history of NSAID intolerance, were classified as "non-AIA". 
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Allergology International j o u r n a l h o m e p a g e : h t t p : / / w w w . e l se v i e r . c o m / l o c a t e / a l i t Between AIA and non-AIA, there were no significant differences with regard to clinical background and lung function (Table 1) . There were no significant differences in PC 20 -AMP and PC 20 -Mch between the two groups (data not shown). However, the ratio of PC 20 -AMP/PC 20 -Mch was significantly lower than that observed in non-AIA patients (ManneWhitney U-test, p ¼ 0.007) (Fig. 1A) . A significant positive correlation was observed between logPC 20 -AMP and logPC 20 -Mch in AIA and non-AIA patients (r ¼ 0.781 and 1.117, respectively, p < 0.001) (Fig. 1B) . Comparative analyses of the two regression slopes showed that individual PC 20 -AMP/ PC 20 -Mch was significantly lower in AIA than in non-AIA (p ¼ 0.02) (Fig. 1B) . These results suggested that sensitivity to AMP was significantly higher in AIA patients compared with non-AIA patients. The ratio of PC 20 -AMP/PC 20 -Mch was a good marker to discriminate between AIA and non-AIA with an area under the receiver-operating-characteristics curve (ROC AUC) of 0.87. Analyses of ROC curves showed that the highest specificity (88.9%) and sensitivity (83.3%) were gained at a cutoff of 15.38 for PC 20 -AMP/PC 20 -Mch (Fig. 1C) .
Recently, it has been recognized that airway MCs have a major role in AIA pathophysiology. 8 Adenosine induces airway hyperresponsiveness through activation of adenosine receptors or P2Y12 receptors (receptor for adenosine diphosphate and leukotriene E4) on MCs. 9 Genetic polymorphism of the gene for the adenosine receptor has been reported to be associated with AIA. 10 Taking these findings into consideration, it appears that adenosine-induced bronchoconstriction in AIA is high specifically because of increased activation of MCs in the airways of AIA patients.
AIA patients exhibit more severe asthmatic symptoms than non-AIA patients, 8 so the diagnosis and appropriate treatment of AIA patients is important. A NSAID-challenge test is essential for the diagnosis of AIA, but is associated with problems such as sensitivity, specificity, and risks. 7 Thus, several trials to investigate better diagnostic methods for AIA have been reported. These trials included in vitro diagnostic methods such as arachidonic-acid derivatives in peripheral blood polymorphonuclear leukocytes or cluster of differentiation (CD)11b expression on the eosinophil surface. 7 Our study suggests that AIA patients may be more sensitive to AMP-induced bronchoconstriction than non-AIA patients, and that bronchial hypersensitivity measured by Mch inhalation was similar in AIA and non-AIA patients. We speculate that the AMP provocation test may reflect MC activation in the airways of AIA patients. Differential hyperresponsiveness of airways to inhalation of AMP and Mch might be a useful marker to distinguish AIA from non-AIA. Letter to the Editor / Allergology International xxx (2016) 1e3
